regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and Novo Regeneron Pharmaceuticals announced on January

Description

however, there are

Semaglutide shows promise in reducing liver fat and improving metabolic markers in patients with fatty liver disease, particularly when combined with structured weight loss

GLP-1 use is rising (even in comp)

This dose delivers stronger appetite suppression, improved craving control, and more consistent fat reductionall with physician oversight for safety and comfort.This is where your body truly begins shifting into weight-loss mode.